Medicinal Cannabis and Mental Health: What the Latest Research Reveals

Despite its growing popularity as a treatment for various conditions, a major new analysis published in The Lancet Psychiatry reveals that medicinal cannabis is not an effective treatment for anxiety, depression, or post-traumatic stress disorder (PTSD). The comprehensive review, the largest of its kind to date, raises significant questions about the widespread leverage of cannabis for mental health symptoms and highlights potential risks associated with its use.

Key Findings of the Landmark Study

Researchers from the University of Sydney’s Matilda Centre conducted a systematic review and meta-analysis of 54 randomized controlled trials (RCTs) spanning 45 years (1980-2025). The study examined both the safety and effectiveness of cannabinoids across a range of mental health conditions. The findings indicate that there is no good evidence to support the use of cannabis for treating anxiety, PTSD, or depression [Scientific American].

Dr. Jack Wilson, lead author of the study, cautioned that routine medicinal cannabis use could potentially worsen mental health outcomes, increasing the risk of psychotic symptoms and cannabis use disorder, and delaying access to more effective treatments [ScienceDaily].

Limited Benefits for Specific Conditions

Whereas the evidence for anxiety, depression, and PTSD is lacking, the research did identify some limited potential benefits for other conditions. These include:

• Cannabis Use Disorder: Cannabis-based treatments showed some promise in helping individuals with cannabis dependence, potentially acting similarly to methadone in opioid-use disorder when combined with psychological therapy [The Lancet].
• Autism Spectrum Disorder: Some evidence suggests a potential reduction in symptoms for individuals with autism, but Dr. Wilson emphasizes that experiences with autism are diverse, and this finding should be interpreted with caution [The Lancet].
• Insomnia: Limited evidence suggests potential benefits for insomnia.
• Tic or Tourette’s Syndrome: Some evidence suggests potential benefits for tic or Tourette’s Syndrome.

However, researchers stress that the quality of evidence supporting these uses is generally low [The Lancet].

Concerning Effects on Substance Use Disorders

The review also revealed a concerning effect in individuals with cocaine-use disorder, where cannabis use actually increased cravings. This finding indicates that medicinal cannabis should not be considered as a treatment option for cocaine dependence and may, in fact, exacerbate the condition [ScienceDaily].

Calls for Stricter Regulation

The increasing use of medicinal cannabis – with approximately 27% of adults aged 16-65 in the United States and Canada reporting medical cannabis use, and roughly half using it for mental health symptoms – has prompted calls for stricter regulation and oversight [ScienceDaily]. Major medical organizations, including the American Medical Association, have expressed concerns about the limited regulation and uncertainty surrounding the effectiveness and safety of these products.

Dr. Wilson emphasizes that the study provides a comprehensive and independent assessment of the benefits and risks of cannabis medicines, which can facilitate clinicians craft evidence-based decisions and ensure patients receive effective treatments while minimizing harm [ScienceDaily].

Looking Ahead

The findings underscore the crucial need for more high-quality research to fully understand the potential benefits and risks of medicinal cannabis. Until more robust evidence is available, caution is advised regarding its use for mental health conditions. Patients should discuss their treatment options with a healthcare professional to determine the most appropriate and effective course of care.